XML 29 R6.htm IDEA: XBRL DOCUMENT v2.4.1.9
Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)
3 Months Ended
Mar. 31, 2015
Mar. 31, 2014
Cash flows from operating activities:    
Net (loss) income $ (427,634)us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest $ 194,834us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
Adjustments to reconcile net income net cash provided by (used in) operating activities:    
Depreciation expense 5,791us-gaap_Depreciation 4,041us-gaap_Depreciation
Amortization of patents 17,323us-gaap_AmortizationOfIntangibleAssets 19,593us-gaap_AmortizationOfIntangibleAssets
Common stock and options for compensation, consulting and vendor services 82,124mlss_CommonStockAndOptionsIssuedForCompensationConsultingAndVendorServices 88,052mlss_CommonStockAndOptionsIssuedForCompensationConsultingAndVendorServices
Changes in operating assets and liabilities:    
(Increase) Decrease in accounts receivable (101,460)us-gaap_IncreaseDecreaseInAccountsReceivable 311,481us-gaap_IncreaseDecreaseInAccountsReceivable
(Increase) Decrease in inventories (268,914)us-gaap_IncreaseDecreaseInInventories (423,294)us-gaap_IncreaseDecreaseInInventories
Decrease to advance on contracts 468,891mlss_IncreaseDecreaseToAdvancesToContractManufacturer 326,197mlss_IncreaseDecreaseToAdvancesToContractManufacturer
(Increase) Decrease to prepaid expenses and other current assets (236,644)us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets (50,866)us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
Decrease in accounts payable (224,393)us-gaap_IncreaseDecreaseInAccountsPayable (803,233)us-gaap_IncreaseDecreaseInAccountsPayable
Increase in Customer Advances   507,345us-gaap_IncreaseDecreaseInCustomerAdvances
Decrease in accrued expenses and other payables (353,976)us-gaap_IncreaseDecreaseInAccruedLiabilities (31,121)us-gaap_IncreaseDecreaseInAccruedLiabilities
Net cash (used in) provided by operating activities (681,191)us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations 276,968us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
Cash flows from investing activities:    
Notes receivable to Milestone Medical Inc (200,000)us-gaap_PaymentsForAdvanceToAffiliate  
Due from related party (184,589)mlss_IncreaseDecreaseInDueFromRelatedPartiesInvestingActivities  
Investment in Medical joint venture (68,387)us-gaap_PaymentsToAcquireOtherInvestments (58,703)us-gaap_PaymentsToAcquireOtherInvestments
Purchases of property and equipment (2,421)us-gaap_PaymentsToAcquirePropertyPlantAndEquipment (4,616)us-gaap_PaymentsToAcquirePropertyPlantAndEquipment
Net cash (used in) investing activities (455,397)us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations (63,319)us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
Cash flows from financing activities:    
Proceeds from exercise of stock options   38,000us-gaap_ProceedsFromStockOptionsExercised
Capital Contribution from noncontrolling interest 100,000us-gaap_ProceedsFromMinorityShareholders  
Net cash provided by financing activities 100,000us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations 38,000us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS (1,036,588)us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease 251,649us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease
Cash and cash equivalents at beginning of period 10,367,993us-gaap_CashAndCashEquivalentsAtCarryingValue 1,147,198us-gaap_CashAndCashEquivalentsAtCarryingValue
Cash and cash equivalents at end of period 9,331,405us-gaap_CashAndCashEquivalentsAtCarryingValue 1,398,847us-gaap_CashAndCashEquivalentsAtCarryingValue
Supplemental disclosure of cash flow information:    
Shares issued to employees in lieu of cash compensation   11,875mlss_StockIssuedEmployeesCompensation
Shares to be issued to directors for prepaid directors' fees   55,200mlss_SharesToBeIssuedToDirectorsForPrepaidDirectorsFees
Medical Joint Venture    
Adjustments to reconcile net income net cash provided by (used in) operating activities:    
(Gain) Loss on joint venture 450,160us-gaap_IncomeLossFromEquityMethodInvestments
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= mlss_MedicalJointVentureMember
130,523us-gaap_IncomeLossFromEquityMethodInvestments
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= mlss_MedicalJointVentureMember
Education Joint Venture    
Adjustments to reconcile net income net cash provided by (used in) operating activities:    
(Gain) Loss on joint venture 4,215us-gaap_IncomeLossFromEquityMethodInvestments
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= mlss_EducationJointVentureMember
3,416us-gaap_IncomeLossFromEquityMethodInvestments
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= mlss_EducationJointVentureMember
China Joint Venture    
Adjustments to reconcile net income net cash provided by (used in) operating activities:    
(Gain) Loss on joint venture $ (96,674)us-gaap_IncomeLossFromEquityMethodInvestments
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= mlss_ChinaJointVentureMember